The Development Of Next Generation Affinity Resins

By Johanna Howson, Mark Hicks, Jade Hopkins, Alvaro Cruz, Gan Zhang and Hans Johansson

Address the need for high capacity, improved stability, and innovative characteristics. Affinity products are increasingly challenged by the development of a wider array of mAb-based therapies requiring specialist purification strategies. Novel therapeutics including bispecific antibodies and Fc-fusion proteins often have unique challenges for both upstream and downstream processes.

Download the scientific poster and view the comparisons study between three molecules: an IgG1 Fc-fusion protein (Fc-Fusion), an IgG4 monoclonal antibody (mAb), and an IgG1 bispecifi c antibody (BsAb).